TruScreen's Capital Raise Announcement

Truscreen Group Limited (ASX: $TRU) has successfully raised NZ$500,000 through an initial share placement of 25,000,000 shares at NZ$0.02 each. The placement, which is part of the company's 15% placement capacity, follows the announcement of a pro rata renounceable rights issue on 12 February 2024. TruScreen is set to conduct an Oversubscription Bookbuild on 14th and 15th March 2024.

Executive Commentary

Tony Ho, Chairman of Truscreen Group Limited, expressed satisfaction with the strong support received at the beginning of the capital raise. He urged shareholders to ensure timely completion of their applications before the closing date on 13 March 2024. In the absence of application forms, shareholders are advised to contact the share registry Link Market Services or the Company Secretary, Guy Robertson.

Summary of TruScreen's Announcement

TruScreen Group Limited (ASX: $TRU) has successfully raised NZ$500,000 through an initial share placement, with firm commitments received for 25,000,000 shares at NZ$0.02 each. The placement, conducted under the company's 15% placement capacity, is part of the ongoing capital raise following the announcement of a pro rata renounceable rights issue. The Chairman, Tony Ho, expressed satisfaction with the strong support received and encouraged shareholders to complete their applications before the closing date. TruScreen's vision of 'A world without the cervical cancer' continues to drive its efforts in developing and manufacturing AI-enabled devices for cervical cancer screening, with a focus on real-time detection of abnormalities in cervical tissue. The company's technology has received recognition and approvals from various regulatory bodies and has been widely used in multiple countries, reflecting its commitment to combating cervical cancer globally.